Description
Shred Injectable (T3 Liothyronine Sodium + SR-9011 + Yohimbine)
- Shred is composed of T3 Liothyronine, SR-9011, and Yohimbine.
- Shred Injectable is offered in a 10ml/100mg per ml/1g formulation, containing 33.3mg per ml of T3 Liothyronine, 33.3mg per ml of SR-9011, and 33.3mg per ml of Yohimbine.
Shred Injectable is a product that combines T3 Liothyronine Sodium, SR-9011, and Yohimbine to explore potential synergies among these compounds. T3 Liothyronine Sodium, recognized for its influence on thyroid function and metabolism, is combined with SR-9011, an agonist of REV-ERB, believed to impact circadian rhythm and metabolic processes. Yohimbine, functioning as an alpha-2 adrenergic receptor antagonist, may affect various physiological functions, including blood flow and fat metabolism. The coalescence of T3 Liothyronine Sodium, SR-9011, and Yohimbine within Shred provides researchers with an avenue to investigate their collective impact on metabolism, energy regulation, and potential fat loss.
| SR-9011 |
|
| CAS Number |
1379686-29-9 |
| Molar Mass |
479.04 g·mol−1 |
| Chemical Formula |
C23H31ClN4O3S |
| IUPAC Name |
3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide |
| Yohimbine |
|
| CAS Number |
146-48-5 |
| Molar Mass |
354.450 g·mol−1 |
| Chemical Formula |
C21H26N2O3 |
| IUPAC Name |
17α-hydroxy-yohimban-16α- carboxylic acid methyl ester |
IML Affiliate Disclosure
Some links on IML may connect readers with third-party suppliers through affiliate arrangements. IML may receive compensation from qualifying transactions at no additional cost to the reader, but the third-party supplier remains responsible for the actual sale, fulfillment, and product documentation.
